Close Menu

miRNA

In PLOS this week: deletion in NME5 linked to primary ciliary dyskinesia in Alaskan Malamutes, study of rabies virus movement in Ontario, and more.

The platform is designed to isolate exosomes from blood, then release their extracellular RNA cargo for analysis as biomarkers for diseases including cancer.

The company missed the analysts' average estimates on the top and bottom lines, but it raised its full-year 2019 revenue guidance.

An international team documented TP53 mutation-related genomic changes across dozens of cancer types using data generated with five platforms for the Cancer Genome Atlas project.

Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.

The firm is applying the isolation tool in cellular therapy for oral cancer by administering a biomarker via bioengineered exosomes to reverse cancer progression.

In PLOS this week: alternatively spliced form of FBXO38 contributes to chronic obstructive pulmonary disease, evolution of the avian influenza virus H9N2, and more.

The funding will be used to support clinical validation and expand market access for the firm's endometriosis diagnostic test.

The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.

With genomic and proteomic profiles for more than 100 colon cancer cases, researchers identified drug targets, treatment resistance insights, potential cancer drivers, and more.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.